Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...
On a "core" basis, which strips out food and energy prices, CPI is forecast to have risen 3.3% over last year in October, ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Revolution Medicines (RVMD – Research Report) today and set ...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...
Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research ...
The Pfizer and Moderna shots are formulated against a virus subtype called KP.2 while the Novavax vaccine targets its parent ...
While it is too early to know how this season’s flu will play out, we do know that COVID-19 is still with us.’ ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Åsa ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Agios Pharma (AGIO – Research Report) today. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback